The present survey will be conducted to collect information on the safety (especially the development of malignant tumors, infections, and other untoward events) and effectiveness of Humira 40 mg/0.8 mL Syringe for Subcutaneous Injection (Humira) in patients receiving the drug for a long period of time for the treatment of rheumatoid arthritis, for the purpose of investigating and confirming factors affecting the safety and effectiveness of the drug.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01163318?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
